|
|
|
|
Vol. 30, Issue 10, 1053-1058, October 2002
Institute of Environmental Medicine, Karolinska Institutet,
Stockholm, Sweden Reactive intermediates are a continuous burden in biology and
several defense mechanisms have evolved. Here we focus on the functions
of glutathione transferases (GSTs) with the aim to discuss the
quantitative aspects of defense against reactive intermediates. Humans
excrete approximately 0.1 mmol of thioether conjugates per day. As the
amount of GST active sites in liver is
Institute of Environmental Medicine, Karolinska Institutet, Stockholm,
Sweden (R.R., R.M.); Karolinska Institutet, Division of Clinical
Pharmacology, Huddinge University Hospital, Stockholm (E.E.); and
Research Drug Metabolism and Pharmacokinetics, Astra-Zeneca R&D,
Södertälje, Sweden (S.S.).
0.5 mmol, it appears
that glutathione transferase catalysts are present in tremendous
excess. In fact, the known catalytic properties of GSTs reveal that the
enzymes can empty the liver glutathione (GSH) pool in a matter
of seconds when provided with a suitable substrate. However, based on
the urinary output of conjugates (or derivatives thereof), individual
GSTs turn over (i.e., catalyze a single reaction) only once every few
days. Glutathione transferase overcapacity reflects the fact that there
is a linear relation between GST enzyme amount and protection level
(provided that GSH is not depleted). Put in a different perspective, a
few reactive molecules will always escape conjugation and reach
cellular targets. It is therefore not surprising that signaling systems
sensing reactive intermediates have evolved resulting in the increase of GSH and GST levels. Precisely for this reason, more moderately reactive electrophiles (Michael acceptors) are receiving growing interest due to their anticarcinogenic properties. Another putative regulatory mechanism involves direct activation of microsomal GST1 by
thiol-reactive electrophiles through cysteine 49. The toxicological significance of low levels of reactive intermediates are
of interest also in drug development, and here we discuss the use of
microsomal GST1 activation as a surrogate detection marker.
This article has been cited by other articles:
![]() |
J. Kool, M. Eggink, H. van Rossum, S. M. van Liempd, D. A. van Elswijk, H. Irth, J. N.M. Commandeur, J. H.N. Meerman, and N. P.E. Vermeulen Online Biochemical Detection of Glutathione-S-Transferase P1-Specific Inhibitors in Complex Mixtures J Biomol Screen, April 1, 2007; 12(3): 396 - 405. [Abstract] [PDF] |
||||
![]() |
T. Tohami, L. Drucker, H. Shapiro, J. Radnay, and M. Lishner Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential FASEB J, March 1, 2007; 21(3): 691 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rius, J. Hummel-Eisenbeiss, A. F. Hofmann, and D. Keppler Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G640 - G649. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, H. G. Shertzer, S. N. Schneider, D. W. Nebert, and T. P. Dalton Glutamate Cysteine Ligase Catalysis: DEPENDENCE ON ATP AND MODIFIER SUBUNIT FOR REGULATION OF TISSUE GLUTATHIONE LEVELS J. Biol. Chem., October 7, 2005; 280(40): 33766 - 33774. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gao, K. Kashfi, and B. Rigas In Vitro Metabolism of Nitric Oxide-Donating Aspirin: The Effect of Positional Isomerism J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 989 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Leslie, A. Haimeur, and M. P. Waalkes Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1): EVIDENCE THAT A TRI-GLUTATHIONE CONJUGATE IS REQUIRED J. Biol. Chem., July 30, 2004; 279(31): 32700 - 32708. [Abstract] [Full Text] [PDF] |
||||